The global cancer supportive care drugs market size is projected to reach USD 22.9 billion by 2026, as per a new report by Grand View Research, Inc. It is expected to progress at a CAGR of 1.0% over the forecast period. Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment.
Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis. Rise in the number of people suffering from the effects of anti-cancer therapies will drive the market, globally. The higher efficacy of supportive care drugs, such as colony stimulating factors (G-CSFs), opioid analgesics, erythropoietins, and antiemetic drugs, among others is anticipated to drive growth of the global cancer supportive care drugs market. High efficiency of these drugs in controlling the adverse effects of cancer and its treatment is projected to drive the demand in near future.
G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.
https://www.grandviewresearch.com/industry-analysis/cancer-supportive-care-drugs-market
Further key findings from the report suggest:
- Some of the key market players are Amgen, Merck, Novartis, Johnson & Johnson, Roche, Helsinn Healthcare, Heron Pharma, Tesaro, and Purdue Pharma. Amgen led the global cancer supportive care market in 2018, capturing over 30% market share
- By therapeutic class, the global ESAs market for CIA was valued at USD 1,838 million in 2018 and is expected to decline with a CAGR of 6.0% over the forecast period. The biologics segment is anticipated to lose its market share due to patent expiration of major brands such as Epogen
- North America led the cancer supportive care drugs market in 2018 and is expected to maintain its position during the forecast period
- Asia Pacific is expected to witness lucrative growth over the forecast period, owing to improvements in healthcare infrastructure and increasing government initiatives
- Late stage pipeline products include non-opioids such as Tanezumab and HTX-011. Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with a superior safety profile
Grand View Research has segmented the global cancer supportive care drugs market based on therapeutic class and region:
Cancer Supportive Care Drugs Therapeutic Class Outlook (Revenue, USD Million, 2015 - 2026)
- G-CSFs (Granulocyte-colony Stimulating Factors)
- ESAs (Erythropoiesis Stimulating Agents)
- Anti-emetics
- Bisphosphonates
- Opioids
- NSAIDs
Cancer Supportive Care Drugs Regional Outlook (Revenue, USD Million, 2015 - 2026)
- North America
- US.
- Canada
- Europe
- UK.
- Germany
- Italy
- France
- Spain
- Asia Pacific
- India
- China
- Japan
- Thailand
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
No comments:
Post a Comment